Literature DB >> 25266309

Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.

Jan J Melenhorst1, Paul Castillo2, Patrick J Hanley3, Michael D Keller3, Robert A Krance2, Judith Margolin2, Ann M Leen2, Helen E Heslop2, A John Barrett4, Cliona M Rooney2, Catherine M Bollard5.   

Abstract

A 12-year-old boy with refractory acute lymphoblastic leukemia received a haploidentical transplant from his mother. As prophylaxis for Epstein-Barr virus (EBV), cytomegalovirus (CMV) and adenovirus, he received ex vivo expanded virus-specific donor T cells 3.5 months after transplant. Four weeks later leukemic blasts bearing the E2A deletion, identified by fluorescent in situ hybridization (FISH), appeared transiently in the blood followed by a FISH-negative hematological remission, which was sustained until a testicular relapse 3.5 months later. Clearance of the circulating leukemic cells coincided with a marked increase in circulating virus-specific T cells. The virus-specific cytotoxic T-cell (CTL) line showed strong polyfunctional reactivity with the patient's leukemic cells but not phytohemagglutinin (PHA) blasts, suggesting that virus-specific CTL lines may have clinically significant antileukemia activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25266309      PMCID: PMC4426803          DOI: 10.1038/mt.2014.192

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  35 in total

1.  Aplastic anaemia in donor cells 14 years after bone-marrow transplant.

Authors:  J J Melenhorst; S A van Luxemburg-Heijs; J E Landegent; R Willemze; W E Fibbe; J H Falkenburg
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

2.  Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.

Authors:  Ronjon Chakraverty; Hyeon-Seok Eom; Jessica Sachs; Jennifer Buchli; Pete Cotter; Richard Hsu; Guiling Zhao; Megan Sykes
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

3.  Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

Authors:  A Gustafsson; V Levitsky; J Z Zou; T Frisan; T Dalianis; P Ljungman; O Ringden; J Winiarski; I Ernberg; M G Masucci
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

4.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.

Authors:  Bipin N Savani; Katayoun Rezvani; Stephan Mielke; Aldemar Montero; Roger Kurlander; Charles S Carter; Susan Leitman; Elizabeth J Read; Richard Childs; A John Barrett
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

5.  Donor T cells to treat EBV-associated lymphoma.

Authors:  H E Heslop; M K Brenner; C M Rooney
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

6.  Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA.

Authors:  J M Fletcher; H G Prentice; J E Grundy
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

7.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

Authors:  S R Riddell; K S Watanabe; J M Goodrich; C R Li; M E Agha; P D Greenberg
Journal:  Science       Date:  1992-07-10       Impact factor: 47.728

8.  Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Authors:  Helen E Heslop; Karen S Slobod; Martin A Pule; Gregory A Hale; Alexandra Rousseau; Colton A Smith; Catherine M Bollard; Hao Liu; Meng-Fen Wu; Richard J Rochester; Persis J Amrolia; Julia L Hurwitz; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

Authors:  Joanne M Hilden; Patricia A Dinndorf; Sharon O Meerbaum; Harland Sather; Doojduen Villaluna; Nyla A Heerema; Ron McGlennen; Franklin O Smith; William G Woods; Wanda L Salzer; Helen S Johnstone; Zoann Dreyer; Gregory H Reaman
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

10.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

Authors:  E A Walter; P D Greenberg; M J Gilbert; R J Finch; K S Watanabe; E D Thomas; S R Riddell
Journal:  N Engl J Med       Date:  1995-10-19       Impact factor: 91.245

View more
  15 in total

1.  Broad spectrum antiviral T cells for viral complications after hematopoietic stem cell transplantation.

Authors:  Britta Maecker-Kolhoff; Britta Eiz-Vesper
Journal:  Ann Transl Med       Date:  2015-05

2.  The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.

Authors:  Austin John Barrett; Catherine M Bollard
Journal:  Ann Transl Med       Date:  2015-04

Review 3.  Improving the safety of T-Cell therapies using an inducible caspase-9 gene.

Authors:  Xiaoou Zhou; Malcolm K Brenner
Journal:  Exp Hematol       Date:  2016-07-26       Impact factor: 3.084

4.  CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.

Authors:  Patrick J Hanley; Jan J Melenhorst; Sarah Nikiforow; Phillip Scheinberg; James W Blaney; Gail Demmler-Harrison; C Russell Cruz; Sharon Lam; Robert A Krance; Kathryn S Leung; Caridad A Martinez; Hao Liu; Daniel C Douek; Helen E Heslop; Cliona M Rooney; Elizabeth J Shpall; A John Barrett; John R Rodgers; Catherine M Bollard
Journal:  Sci Transl Med       Date:  2015-04-29       Impact factor: 17.956

Review 5.  CAR T Cell Locomotion in Solid Tumor Microenvironment.

Authors:  Duy T Nguyen; Elizabeth Ogando-Rivas; Ruixuan Liu; Theodore Wang; Jacob Rubin; Linchun Jin; Haipeng Tao; William W Sawyer; Hector R Mendez-Gomez; Matthew Cascio; Duane A Mitchell; Jianping Huang; W Gregory Sawyer; Elias J Sayour; Paul Castillo
Journal:  Cells       Date:  2022-06-20       Impact factor: 7.666

Review 6.  T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Authors:  Catherine M Bollard; Helen E Heslop
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

Review 7.  Modern approaches to HLA-haploidentical blood or marrow transplantation.

Authors:  Christopher G Kanakry; Ephraim J Fuchs; Leo Luznik
Journal:  Nat Rev Clin Oncol       Date:  2015-08-25       Impact factor: 66.675

Review 8.  Chimeric antigen receptors: driving immunology towards synthetic biology.

Authors:  Michel Sadelain
Journal:  Curr Opin Immunol       Date:  2016-06-30       Impact factor: 7.486

9.  Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.

Authors:  Vijayendra Dasari; Andrea Schuessler; Corey Smith; Yide Wong; John J Miles; Mark J Smyth; George Ambalathingal; Ross Francis; Scott Campbell; Daniel Chambers; Rajiv Khanna
Journal:  Mol Ther Methods Clin Dev       Date:  2016-08-24       Impact factor: 6.698

10.  Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response.

Authors:  Corey Smith; Victor Lee; Andrea Schuessler; Leone Beagley; Sweera Rehan; Janice Tsang; Vivian Li; Randal Tiu; David Smith; Michelle A Neller; Katherine K Matthews; Emma Gostick; David A Price; Jacqueline Burrows; Glen M Boyle; Daniel Chua; Benedict Panizza; Sandro V Porceddu; John Nicholls; Dora Kwong; Rajiv Khanna
Journal:  Oncoimmunology       Date:  2017-01-04       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.